NCT06174935 is a Phase 2 clinical trial of 0.01% atropine ophthalmic drop in Vitreous Floaters, sponsored by Jeanette Du.

Who is sponsoring NCT06174935?

NCT06174935 is sponsored by Jeanette Du.

What drugs are being tested in NCT06174935?

Interventions in NCT06174935: 0.01% atropine ophthalmic drop.

What condition does NCT06174935 study?

NCT06174935 studies Vitreous Floaters.

Is NCT06174935 still recruiting?

NCT06174935 is currently status unknown. Last updated 18 December 2023.

Last reviewed 2023-12-18 · How we verify

NCT06174935

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Low Dose Atropine for Symptomatic Vitreous Floaters

Status unknown Phase 2 Last updated 18 December 2023

What this trial tests

Phase 2 trial testing 0.01% atropine ophthalmic drop in Vitreous Floaters in 200 participants. Status unknown.

Timeline

1 January 2024

Primary endpoint
1 June 2024

1 June 2024

Quick facts

Lead sponsor	Jeanette Du
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	200
Start date	1 January 2024
Primary completion	1 June 2024
Estimated completion	1 June 2024
Sites	1 location across United States

Drugs / interventions tested

0.01% atropine ophthalmic drop — full drug profile →

Conditions studied

Vitreous Floaters — all drugs for Vitreous Floaters →

Sponsor

Jeanette Du — full company profile →

Who can join

19 and older, any sex, with Vitreous Floaters. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The objective of this study is to identify a potential pharmacologic option by assessing whether 0.01% atropine may be effective for treating bothersome floaters as measured by scores on a modified NEI VFQ-25.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Vitreous Floaters

Currently open trials in the same condition.

NCT06964867 — Effectiveness of Multimedia Health Education to Reduce Anxiety in Patients With Vitreous Floaters · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06174935 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Jeanette Du
Last refreshed: 18 December 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06174935.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing